FRESENIUS SE+CO. ADR 1/4 Market Cap ($26.87 Billion)
Market Cap & Net Worth: FRESENIUS SE+CO. ADR 1/4 (FREA)
FRESENIUS SE+CO. ADR 1/4 market cap. FRESENIUS SE+CO. ADR 1/4 (F:FREA) has a market capitalization of $26.87 Billion (€22.98 Billion) as of October 31, 2026. Listed on the F stock exchange, this Germany-based company holds position #987 globally and #223 in its home market, demonstrating a -6.42% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying FRESENIUS SE+CO. ADR 1/4's stock price €10.20 by its total outstanding shares 2252949108 (2.25 Billion).
FRESENIUS SE+CO. ADR 1/4 Market Cap History (2015–2026)
FRESENIUS SE+CO. ADR 1/4 market cap history from 2015 to 2026. Data shows change from $36.41 Billion to $30.03 Billion (-2.02% CAGR). Check FRESENIUS SE+CO. ADR 1/4 share price for real-time trading data and today's change.
FRESENIUS SE+CO. ADR 1/4 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how FRESENIUS SE+CO. ADR 1/4's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see FRESENIUS SE+CO. ADR 1/4 cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
1.36x
FRESENIUS SE+CO. ADR 1/4's market cap is 1.36 times its annual revenue
Latest Price to Earnings (P/E) Ratio
24.59x
FRESENIUS SE+CO. ADR 1/4's market cap is 24.59 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $21.46 Billion | $37.52 Billion | $1.82 Billion | 0.57x | 11.80x |
| 2022 | $16.37 Billion | $21.53 Billion | $1.37 Billion | 0.76x | 11.93x |
| 2023 | $18.44 Billion | $21.07 Billion | -$594.00 Million | 0.88x | N/A |
| 2024 | $21.60 Billion | $21.95 Billion | $471.00 Million | 0.98x | 45.86x |
| 2025 | $31.08 Billion | $22.87 Billion | $1.26 Billion | 1.36x | 24.59x |
Competitor Companies of FREA by Market Capitalization
Companies near FRESENIUS SE+CO. ADR 1/4 in the global market cap rankings as of October 31, 2026. See FRESENIUS SE+CO. ADR 1/4 (FREA) balance sheet quality index to understand what proportion of total assets are financed by equity.
Key companies related to FRESENIUS SE+CO. ADR 1/4 by market ranking:
- HCA Healthcare, Inc. (NYSE:HCA): Ranked #284 globally with a market cap of $91.34 Billion USD.
- Fresenius SE & Co. KGaA (XETRA:FRE): Ranked #901 globally with a market cap of $29.19 Billion USD ( €24.97 Billion EUR).
- Tenet Healthcare Corporation (NYSE:THC): Ranked #1210 globally with a market cap of $20.93 Billion USD.
- IHH Healthcare Bhd (KLSE:5225): Ranked #1413 globally with a market cap of $17.41 Billion USD ( RM69.36 Billion MYR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #284 | HCA Healthcare, Inc. | NYSE:HCA | $91.34 Billion | $473.19 |
| #901 | Fresenius SE & Co. KGaA | XETRA:FRE | $29.19 Billion | €47.80 |
| #1210 | Tenet Healthcare Corporation | NYSE:THC | $20.93 Billion | $273.25 |
| #1413 | IHH Healthcare Bhd | KLSE:5225 | $17.41 Billion | RM7.85 |
Market Capitalization of FRESENIUS SE+CO. ADR 1/4 (2015–2026)
Market capitalization of FRESENIUS SE+CO. ADR 1/4 from 2015 to today. Between 2015 and today, FRESENIUS SE+CO. ADR 1/4's market cap moved from $36.41 Billion to $ 30.03 Billion, with a yearly change of -2.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €30.03 Billion | -3.39% |
| 2025 | €31.08 Billion | +43.90% |
| 2024 | €21.60 Billion | +17.14% |
| 2023 | €18.44 Billion | +12.63% |
| 2022 | €16.37 Billion | -23.72% |
| 2021 | €21.46 Billion | -5.20% |
| 2020 | €22.64 Billion | -21.55% |
| 2019 | €28.86 Billion | +21.66% |
| 2018 | €23.72 Billion | -34.44% |
| 2017 | €36.18 Billion | -11.41% |
| 2016 | €40.84 Billion | +12.17% |
| 2015 | €36.41 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of FRESENIUS SE+CO. ADR 1/4 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $26.87 Billion USD |
| MoneyControl | $26.87 Billion USD |
| MarketWatch | $26.87 Billion USD |
| marketcap.company | $26.87 Billion USD |
| Reuters | $26.87 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About FRESENIUS SE+CO. ADR 1/4
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through Fresenius Kabi and Fresenius Helios segment. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machin… Read more